Search hospitals > Michigan > Ann Arbor
University of Michigan Comprehensive Cancer Center
Claim this profileAnn Arbor, Michigan 48109
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Prostate Cancer
856 reported clinical trials
59 medical researchers
Summary
University of Michigan Comprehensive Cancer Center is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Lymphoma, Prostate Cancer and other specialties. University of Michigan Comprehensive Cancer Center is involved with conducting 856 clinical trials across 627 conditions. There are 59 research doctors associated with this hospital, such as Paul Swiecicki, Rashmi Chugh, MD, Francis P. Worden, and Rama Jasty.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Paul SwiecickiUniversity of Michigan Comprehensive Cancer Center1 year of reported clinical research
Expert in Cancer
Studies Squamous Cell Carcinoma
19 reported clinical trials
29 drugs studied
Rashmi Chugh, MDUniversity of Michigan4 years of reported clinical research
Studies Sarcoma
Studies Tumors
18 reported clinical trials
24 drugs studied
Francis P. WordenUniversity of Michigan5 years of reported clinical research
Studies Cancer
Studies Thyroid Cancer
13 reported clinical trials
23 drugs studied
Rama JastyC S Mott Children's Hospital6 years of reported clinical research
Studies Tumors
Studies Cancer
11 reported clinical trials
28 drugs studied
Clinical Trials running at University of Michigan Comprehensive Cancer Center
Breast Cancer
Cancer
Pancreatic Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Prostate Cancer
Lymphoma
Colorectal Cancer
Tumors
Lung Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Michigan Comprehensive Cancer Center?
University of Michigan Comprehensive Cancer Center is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Lymphoma, Prostate Cancer and other specialties. University of Michigan Comprehensive Cancer Center is involved with conducting 856 clinical trials across 627 conditions. There are 59 research doctors associated with this hospital, such as Paul Swiecicki, Rashmi Chugh, MD, Francis P. Worden, and Rama Jasty.
Where is University of Michigan Comprehensive Cancer Center located?
To reach the University of Michigan Comprehensive Cancer Center in Ann Arbor from US-23 North, use the Washtenaw Ave./BR23 exit (#37B). From US-23 South, take the Plymouth Road exit (#41). Follow the signs to Medical Center Drive where the Cancer Center is located. Parking is available in Structure P1, adjacent to the Cancer Center, for patients and their families.
Who should I call to ask about financial aid or insurance network?
The University of Michigan Comprehensive Cancer Center provides financial assistance and insurance support, including a financial assistance program offering a 60% discount for uninsured patients, potentially qualifying for free care for certain services. Patients can apply by downloading the application form available in multiple languages. For insurance matters, the center accepts most plans and advises patients to verify coverage with their health plan before scheduling appointments. Assistance with expenses, transportation, and billing questions is available through the Patient Assistance Center, reachable at 855-855-0863 or 734-615-0863, Monday - Friday, 8:30 a.m. - 6 p.m.
What insurance does University of Michigan Comprehensive Cancer Center accept?
The University of Michigan Comprehensive Cancer Center accepts a wide range of insurance plans, including Medicare, Medicaid, Blue Cross Blue Shield of Michigan (BCBSM), Blue Care Network (BCN), among others. Accepted insurance plans may vary by service type, including laboratory services and cancer treatment. For the most current information on accepted insurance, please contact the hospital directly.
What awards or recognition has University of Michigan Comprehensive Cancer Center received?
The University of Michigan Rogel Cancer Center, located in Ann Arbor, Michigan, is distinguished as a comprehensive cancer center by the National Cancer Institute (NCI), receiving a $37 million grant for research across basic science, translational research, clinical research, and population sciences. It holds recognition from the Quality Oncology Practice Initiative (QOPI®) and is part of the Michigan Cancer Consortium, the Big Ten Cancer Research Consortium, and the Commission on Cancer (CoC) of the American College of Surgeons.